Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-21

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase 2a clinical trial on up to n=200 male and female subjects 18 years and over who were diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Subjects are randomised in approximately a 1:1 ratio to receive standard of care treatment plus either pyronaridine (PND) or placebo. Quality of life parameters are measured. Visits include physical examinations, and blood draws for complete blood count with differential (CBC) and complete metabolic panel (CMP). Survival of subjects is tracked in Year 2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

NCT01814826

Acute Myelogenous Leukemia

COMPLETED PHASE1

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

NCT00131053

Lymphoblastic Leukemia, Acute

UNKNOWN PHASE2

Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

NCT01540812

Acute Lymphoblastic Leukemia

COMPLETED

A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

NCT02864290

Acute Myeloid Leukemia

TERMINATED PHASE1

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

NCT02881086

Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is the difference in survival lengths in days between the study arm receiving pyronaridine and the study arm receiving placebo as measured from the date of the first diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Secondary objectives are differences between the active and placebo study arms in quality of life, laboratory data values and in the safety and tolerability of treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The primary objective is the difference in survival lengths in days between the study arm receiving pyronaridine and the study arm receiving placebo as measured from the date of the first diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL).

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

All capsules contain either pyronaridine or similar-appearing placebo.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of care treatment plus pyronaridine

Group Type ACTIVE_COMPARATOR

Pyronaridine Tetraphosphate

Intervention Type DRUG

Via oral capsules.

Standard of care treatment plus placebo

Group Type PLACEBO_COMPARATOR

Pyronaridine Tetraphosphate

Intervention Type DRUG

Via oral capsules.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pyronaridine Tetraphosphate

Via oral capsules.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects must have a diagnosis within 60 days of the time of study entry of either acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). If the physician is a third-party physician, then the study site must obtain the subject's medical records from the clinic where the first diagnosis was made.
2. Subjects must be on standard of care therapy for ALL or AML. The standard of care therapy may be initiated at time of study entry.
3. Subjects must be 18 years of age or older, and male or female.
4. Subjects must weigh between 40kg and 90kg at time of study entry.
5. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) at least 14 days prior to study entry, for the duration of study participation, and at least 30 days after completion of drug administration. Women of child-bearing potential must agree to pregnancy tests for the duration of the study. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the study subject should inform her investigator immediately.
6. Men must agree to always use a condom during intercourse for the duration of study participation, and for at least 30 days after completion of drug administration.
7. Subjects must have the ability to swallow size "0" gelatin capsules.
8. Subject must be willing to agree to and comply with all requirements of the study.
9. Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

1. Subjects with malaria.
2. Subjects who are pregnant or nursing.
3. Subjects who have had major surgery within 30 days prior to study entry.
4. Subjects with active clinically significant infection or uncontrolled illness, except ALL or AML.
5. Subjects with evidence of chronic hepatitis B (HBV) infection.
6. Subjects with evidence or history of hepatitis C (HCV) infection.
7. Subjects with a prior or concurrent malignancy (basal cell carcinoma and squamous cell skin cancer are allowed).
8. Subjects with evidence of other disease or any concomitant medical or psychiatric problem which in the opinion of the investigator would put them at risk.
9. Subjects with a known hypersensitivity to pyronaridine tetraphosphate or compounds of similar chemical composition, or microcrystalline cellulose (MCC) the placebo agent.
10. Subjects who are receiving any other investigational agents or who have received any investigational medication within the past 30 days.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes